adrenal gland tissue, 5 and microRNA-34b expression was reported to be decreased in non-small-cell lung cancers. 4 Here, we show for the first time that microRNA-34a is significantly downregulated in CLL patients with TP53 deletions compared with CLL patients without such deletions. In these cases, we were not able to reveal BCL2 as a target of microRNA34a. Still, BCL2 being only one of the microRNA-34a targets, a potential function of a regulatory circuit involving the important tumor suppressor TP53 and microRNA-34a in the pathogenesis of CLL cannot be excluded, and needs to be further investigated.
Enhanced tyrosine kinase activity due to constitutively activated ABL1 plays an important role in several leukemias. The BCR-ABL1 fusion gene is the cytogenetic hallmark of chronic myeloid leukemia (CML) and is also frequently observed in B-cell acute lymphoblastic leukemia (ALL), but is exceptionally rare in T-ALL. However, amplification of ABL1 may be observed in up to 6% of T-ALL patients, as was initially described by Barber et al. 1 Amplification of ABL1 appeared to be due to a cryptic episomal fusion of NUP214 to ABL1, which was first described by Graux et al. 2 Apart from fluorescence in situ hybridization (FISH) to visualize the ABL1 on the episomes, real-time quantitative polymerase chain reaction (PCR) may be used for diagnosis and monitoring of response and minimal residual disease. 3 Targeting of the pathogenetically relevant BCR-ABL1 tyrosine kinase with the kinase inhibitor imatinib has been a major breakthrough in the management of patients with CML and Philadelphia-positive ALL. In vitro, the constitutively activated tyrosine kinase NUP214-ABL1 appeared sensitive to the tyrosine kinase inhibitor imatinib in T-ALL cell lines carrying the NUP214-ABL1 transcript. 2 This finding provided the rationale to introduce kinase inhibitor therapy in the treatment of patients with this specific fusion gene. So far, only one patient with a relapsed NUP214-ABL1-positive T-ALL failing imatinib monotherapy, was described. 4 Given the possibility of imatinib resistance because of extensive amplification of ABL1 and the more potent inhibition exerted by dasatinib (formerly BMS-354825), we hypothesized that dasatinib may be preferred for treatment of NUP214-ABL1-positive ALL. Here, we describe the first patient with a NUP214-ABL1-positive T-ALL, who favorably responded to dasatinib monotherapy. This report provides the rationale to introduce the more potent kinase inhibitors in the treatment of NUP214-ABL1-positive T-cell ALL.
A 21-year-old man with a 3-day history of progressive abdominal pain was referred to the emergency ward. There was no history of abdominal trauma, no recent infections were reported and no fever had been noticed. He also denied nausea, vomiting, or alteration in bowel or bladder habits. Physical examination showed an acute ill patient with a temperature of 39 1C. He was hypotensive and abdominal examination revealed 'defense musculaire', suggesting peritoneal inflammation (acute abdomen). Laboratory findings at admission included a hemoglobin level of 6.4 g per 100 ml, a white blood cell count of 41 Â 10 9 /l with 87% of lymphoblasts in the differential and a platelet count of 20 Â 10 9 /l. Following transfusion of erythrocytes, platelets and fluids, the patient was stabilized and offered for surgery. At laparotomy, rupture of an enlarged spleen was found, which necessitated a splenectomy. Meanwhile, morphology and immunophenotyping of blood and bone marrow showed malignant blasts positive for CD45, TDT, cyCD3, CD5, CD2, CD1a, CD4, CD8 and CD10, without expression of other B-lymphoid markers or myeloid markers. These findings established a diagnosis of a common T-cell ALL. Histology of the spleen showed extensive infiltration of T-lymphoblasts and further examination by a computed tomography scan showed an enlarged mediastinum and mediastinal and abdominal lymphadenopathy. Cytogenetics revealed no abnormalities, but extrachromosomal amplification of ABL1 was demonstrated by FISH using the LSI BCR/ABL ES Dual Color Translocation Probe (Vysis), suggesting a NUP214-ABL1 fusion, which was subsequently confirmed by real-time quantitative polymerase chain reaction (primers NUP214-ABL1 FOR 5 0 -CCTCTGGGTTCAGCT TTT-3 0 , and REV 3 0 -TCAGACCCTGAGGCTCAAAGTC-5 0 and probe ABL1 6-FAM 5 0 -AAGCCCTTCAGCGGCCAGTAGC A-3 0 TAMRA; reference gene PBGD FOR 5 0 -GGCAATGCGGCT GCAA-3 0 and REV 5 0 -GGGTACCCACGCGAATCAC-3 0 and probe PBGD 6-FAM 5 0 -CATCTTTGGGCTGTTTTCTTCCG CC-3 0 TAMRA; annealing 58 1C). Given the FISH findings, and a protracted abdominal recovery after surgery, immediate start of intensive combination chemotherapy was postponed and the patient was started with 70 mg of dasatinib two times daily (Table 1) , following informed consent. After 3 weeks of treatment with dasatinib monotherapy, the patient achieved a complete hematologic and complete cytogenetic remission. Assessment of minimal residual disease by flow cytometry and by quantitative PCR showed 0.4 % residual T-lymphoblasts and a reduction of 2 log of NUP214-ABL1 copies as compared to baseline level, respectively. At that time, the patient had recovered from surgery, and induction chemotherapy was started (vincristine, prednisone and daunorubicine according to the HOVON-37 protocol, but without asparaginase), in combination with dasatinib. Dasatinib was very well tolerated throughout the treatment course and no side effects were noted. Following consolidation with cytarabine and mitoxantrone, consolidation with high-dose methotrexate and asparaginase was given, whereas dasatinib was temporarily interrupted during the phase of asparaginase. Side effects of chemotherapy included two episodes of neutropenic fever, and transient common toxicity criteria grade 1-2 mucositis. A complete immunological and molecular remission ensued after the first consolidation course of chemotherapy. At the time of initial neutrophil recovery following the first consolidation, granulocyte colony-stimulating factor (G-CSF) was given for mobilization of peripheral blood stem cells and the harvest of a peripheral blood stem cell graft. A sufficient number of CD34-positive progenitor cells were harvested and the molecular evaluation of the graft did not reveal minimal residual disease by real-time quantitative polymerase chain reaction. Lacking a matched sibling donor, the patient qualified for autologous stem cell transplantation according to the HOVON-37 protocol, which was performed at 6 months from diagnosis following myeloablative conditioning with cyclophosphamide and total body irradiation (12 Gy in 2 fractions). The posttransplant course was uneventful and following full hematologic recovery, the patient was restarted on dasatinib, which will be continued as maintenance therapy for 2 years. His latest bone marrow examination at 3 months after transplantation showed persistent molecular remission.
Constitutively activated tyrosine kinases may be involved in the pathogenesis of several myeloid and lymphoid leukemias. Examples of hematologic malignancies, in which constitutively activated tyrosine kinases play a major pathogenetic role, include BCR-ABL1 in CML and ALL, PDGFR-a in the hypereosinophilic syndromes, FLT3 in acute myeloid leukemia and NUP214-ABL1 in ALL as was also present in this case. Although BCR-ABL1 and NUP214-ABL1 share a common tyrosine kinase domain, there are also many differences including a different activation state and conformation of the two ABL1 fusion kinases, substrate preference and inhibitory sensitivity as was recently reported. 5 Analysis of the transforming properties and structure-function studies have enabled the development of small molecules that specifically inhibit activated kinases. Imatinib mesylate was the first of these drugs that has entered clinical medicine, and has revolutionized the treatment of CML. Other inhibitors of BCR-ABL1 include nilotinib and dasatinib. Nilotinib (formerly AMN107) exerts a higher and more specific binding affinity for the ABL1 kinase, appeared active against many imatinib-resistant ABL1 mutants, but binds ABL1 kinase in its inactive conformation only. Dasatinib on the other hand binds ABL1 both in its active and inactive conformation, resulting in a 10-fold higher potency than nilotinib and is active against most imatinib-resistant ABL1 kinase domain mutants. In addition, dasatinib also inhibits the kinase activity of many other kinases, including the SRC family. LCK, a member of the SRC family of tyrosine kinases, is highly expressed in T-cells and plays an important role in the initiation of the T-cell receptor-signaling pathway. De Keersmaecker et al. 6 showed that LCK was critical for NUP214-ABL1 signaling, and they suggested that LCK was an interesting alternative target in NUP214-ABL1-positive patients, when they were searching for other therapeutic targets in these patients. Recently, QuintasCardama et al. 7 examined and compared the activity of imatinib, nilotinib and dasatinib in several human NUP214-ABL1-positive T-cell lines as well as patient-derived lymphoblasts. Although all three inhibitors showed inhibition of cellular proliferation and induction of apoptosis, especially Letters to the Editor dasatinib appeared associated with strong apoptotic effects and inhibition of phosphorylation. Moreover, a significant prolongation of survival was observed in a murine xenograft leukemia model following treatment with dasatinib as compared with placebo. Therefore, based on these findings as well as on the demonstrated inhibitory activity against the SRC-kinases, dasatinib may be preferred as an inhibitor in NUP214-ABL1 T-ALL patients. These considerations are now strongly underpinned by the striking clinical activity as observed in our patient.
Our results suggest that every effort has to be taken to establish an early diagnosis of the episomal NUP214-ABL1 amplification in patients with T-ALL, which is to be followed then by incorporation of dasatinib in the chemotherapy schedules. Preferably, a combination of dasatinib and chemotherapy should be given. Although the presence of the NUP214-ABL1 fusion was not associated with a very poor outcome in the German series of patients, overall outcome was still unsatisfactory and estimated approximately 50% at 5 years. 3 Addition of dasatinib may be expected to improve the outcome of these patients considerably, but an improvement of approximately 20% might already be considered as a major step forward. It implies that a reduction of the intensity of the current chemotherapy should be considered as too early. What about the application of stem cell transplantation ? The use of autologous stem cell transplantation in ALL, as applied in our patient, has been debated repeatedly. 8 However, the introduction of myeloablative irradiation offers the advantage of introducing radiotherapy in patients with T-ALL, who often present with extensive extramedullary leukemia, as was observed in this case. Similar to patients with BCR-ABL1-positive B-ALL, we choose to continue dasatinib maintenance guided by regular monitoring of residual disease by PCR every 3 months, which may enable a diagnosis of an imminent relapse.
In conclusion, FISH with probes for ABL1 should be included in the work-up of T-ALL patients, to rapidly demonstrate the presence of the NUP214-ABL1 episomal amplification. Based on extensive in vitro findings 6, 7 as well as the present case report, dasatinib may then be the preferred inhibitor to be combined with standard chemotherapy schedules. The inclusion of these patients into an international protocol standardizing treatment allows to address important clinical and biological questions in this particular and rare subset of T-ALL. 
